NSE · VINEETLAB · Basic Materials
Vineet Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹77 Cr with net profit ₹-20 Cr — a -26.23% net margin, versus 0.68% the period before.
Shareholding
As of 2026-03-31
- Promoter5.98%
- Public93.66%
- FII0.36%
9,929 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.76× from low to high.
Risk flags
Derived from disclosed data
- Reported zero revenue in 2 of the last 7 disclosed periods.
Peer comparison
Chemicals · ranked #116 of 159 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Pidilite Industries Ltd. | ₹1,65,890 Cr | 67.35 | 15.31 | 22.61% | 16.77% |
| Solar Industries India Ltd. | ₹1,63,362 Cr | 93.51 | 26.02 | 26.72% | 17.05% |
| SRF Ltd. | ₹77,213 Cr | 34.46 | 5.5 | 13.07% | 13.01% |
| Linde India Limited | ₹56,603 Cr | 103.24 | 13.27 | 12.87% | 21.69% |
| Gujarat Fluorochemicals Ltd. | ₹48,279 Cr | 443.04 | 6.19 | 7.3% | 11.49% |
| Godrej Industries Ltd. | ₹44,101 Cr | 99.27 | 3.95 | 11.1% | 5.58% |
| Himadri Speciality Chem Limited | ₹38,370 Cr | 191.08 | 8.15 | 15.96% | 16.12% |
| Navin Fluorine International Ltd. | ₹37,898 Cr | 58.47 | 9.53 | 16.69% | 20.02% |
| Deepak Nitrite Ltd. | ₹22,422 Cr | 102.04 | 3.84 | 9.43% | 6.98% |
| Atul Ltd. | ₹20,029 Cr | 95.31 | 3.22 | 9.31% | 8.93% |
| Vineet Laboratories Ltd.(this company) | ₹75 Cr | 42.62 | 1.69 | -117.41% | -18.59% |
AI analysis
AI-generated · google/gemini-2.5-flashVineet Laboratories Ltd. has a market capitalization of Rs 72 Cr. The company reported revenue of Rs 76.98 Cr in the latest fiscal year. Its book value is Rs 15.89. The company's EPS is -21.9 and it has a negative ROCE of -22.411%.
Positives
- +The promoter pledge is 0%, indicating no shares are pledged.
- +FII holding has a presence at 0.36% as of March 2026.
Negatives
- −The company reported a negative EPS of -21.9 in Mar 2025.
- −Revenue has significantly declined to Rs 76.98 Cr in Mar 2025 from Rs 243.86 Cr in Mar 2021.
- −The company reported a net loss of Rs -20.19 Cr in Mar 2025.
- −Return on Capital Employed (ROCE) is negative at -22.411%.
- −Promoter holding has decreased substantially from 38.66% in Mar 2023 to 5.98% in Mar 2026.
- −The debt-to-equity ratio is high at 1.71.
Financial performance
Vineet Laboratories Ltd. has experienced a decline in revenue over recent years. Revenue decreased from Rs 243.86 Cr in Mar 2021 to Rs 76.98 Cr in Mar 2025. Net profit also saw a significant drop, falling from Rs 1.78 Cr in Mar 2021 to a net loss of Rs -20.19 Cr in Mar 2025. The company's latest annual EBITDA was -16.79 Cr in Mar 2025.
Profitability & returns
The company's profitability has deteriorated, with a negative EPS of -21.9 in Mar 2025, down from 1.11 in Mar 2024. Return on Capital Employed (ROCE) is significantly negative at -22.411%. Return on Equity (ROE) is 0%, reflecting no returns for equity shareholders. The net profit has moved from positive to negative, reporting a loss of Rs -20.19 Cr in Mar 2025.
Balance sheet
Vineet Laboratories Ltd. has a debt-to-equity ratio of 1.71, indicating a reliance on debt financing. The book value per share is Rs 15.89. The company's EBITDA for Mar 2025 was -16.79 Cr, while its net profit was -20.19 Cr in the same period.
Ownership & pledges
Public shareholding is dominant at 93.66%. There are no shares pledged by the promoters.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.